Company profile
Capricor Therapeutics, Inc.
Pipeline4 assets
- DeramiocelCAP-1002 / allogeneic CDCs / Neuromuscular diseaseDuchenne muscular dystrophy (DMD)Phase 3in progressBecker muscular dystrophy (BMD)Preclinicalin progress
- StealthX™STX-S / Exosome-based vaccine / Infectious diseaseSARS-CoV-2Phase 1in progress
- StealthX™Therapeutic ExosomesEvaluatingPreclinicalin progress
- CDC-ExosomesExosome Platform / Neuromuscular diseaseDuchenne muscular dystrophyPreclinicalin progress
Latest news14 items
All newsCapricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Presentation / Abstract • Phase 3Late-breaking presentation Sat, Jun 27, 2026
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Presentation / Abstract • Phase 3